Literature DB >> 11096719

Complex Partial Seizures in Adults.

.   

Abstract

Many disorders can mimic complex partial seizure (CPS), and clinicians must be careful to make an accurate diagnosis. Complex partial seizures must be distinguished from generalized-onset seizures (such as absence seizures), which require a different treatment regimen. Treatment of CPS should begin with monotherapy with a standard antiepileptic drug (AED), such as phenytoin or carbamazepine. Increasing evidence indicates that the newer AEDs, such as lamotrigine, topiramate, and possibly gabapentin, are effective as monotherapy. These AEDs may prove to be as effective as the standard AEDs but with fewer adverse effects. All the newer AEDs have significant efficacy when used as add-on treatments, and they may have fewer adverse effects than standard AEDs used in combination. Surgery for epilepsy should be considered in any patient in whom adequate trials of AEDs have failed. The vagus nerve stimulator, a new nonpharmacologic treatment, is a reasonable option in patients in whom AED treatment has failed. Randomized clinical trials comparing older and newer AEDs in the treatment of CPS are needed.

Entities:  

Year:  1999        PMID: 11096719     DOI: 10.1007/s11940-999-0022-8

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  38 in total

Review 1.  A mechanistic approach to antiepileptic drug interactions.

Authors:  G D Anderson
Journal:  Ann Pharmacother       Date:  1998-05       Impact factor: 3.154

2.  Felbamate: a clinical trial for complex partial seizures.

Authors:  W H Theodore; R F Raubertas; R J Porter; F Nice; O Devinsky; P Reeves; E Bromfield; B Ito; M Balish
Journal:  Epilepsia       Date:  1991 May-Jun       Impact factor: 5.864

3.  Clorazepate and phenobarbital as antiepileptic drugs: a double-blind study.

Authors:  A J Wilensky; L M Ojemann; N R Temkin; A S Troupin; C B Dodrill
Journal:  Neurology       Date:  1981-10       Impact factor: 9.910

4.  Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. The US Gabapentin Study Group No. 5.

Authors: 
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

5.  Alcohol consumption and withdrawal in new-onset seizures.

Authors:  S K Ng; W A Hauser; J C Brust; M Susser
Journal:  N Engl J Med       Date:  1988-09-15       Impact factor: 91.245

6.  Relation of photosensitivity to epileptic syndromes.

Authors:  P Wolf; R Goosses
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-12       Impact factor: 10.154

7.  Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures.

Authors:  R H Mattson; J A Cramer; J F Collins; D B Smith; A V Delgado-Escueta; T R Browne; P D Williamson; D M Treiman; J O McNamara; C B McCutchen
Journal:  N Engl J Med       Date:  1985-07-18       Impact factor: 91.245

8.  A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group.

Authors:  R H Mattson; J A Cramer; J F Collins
Journal:  N Engl J Med       Date:  1992-09-10       Impact factor: 91.245

9.  A double-blind study comparing carbamazepine with phenytoin as initial seizure therapy in adults.

Authors:  R E Ramsay; B J Wilder; J R Berger; J Bruni
Journal:  Neurology       Date:  1983-07       Impact factor: 9.910

10.  Felbamate monotherapy: controlled trial in patients with partial onset seizures.

Authors:  R Sachdeo; L D Kramer; A Rosenberg; S Sachdeo
Journal:  Ann Neurol       Date:  1992-09       Impact factor: 10.422

View more
  1 in total

1.  Topiramate and its effect on fMRI of language in patients with right or left temporal lobe epilepsy.

Authors:  Jerzy P Szaflarski; Jane B Allendorfer
Journal:  Epilepsy Behav       Date:  2012-04-04       Impact factor: 2.937

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.